| |||
 | |||
 |
Creatine | ||
|
Tyrosine | ||
| |||
| Pronunciation |
 (kar
AM i fen & fen il proe pa
NOLE a meen) |
 |
| U.S. Brand Names |
| Ordrine AT® Extended Release Capsule; Rescaps-D® S.R. Capsule; Tuss-Allergine® Modified T.D. Capsule; Tussogest® Extended Release Capsule |
|
| Generic Available |
|
Yes |
|
| Synonyms |
| Phenylpropanolamine and Caramiphen |
|
| Pharmacological Index |
|
Antihistamine |
|
| Use |
|
Symptomatic relief of cough and nasal congestion associated with the common cold |
|
| Pregnancy Risk Factor |
|
C |
|
| Contraindications |
|
Concurrent MAO inhibitor therapy; bronchial asthma; severe hypertension; hypersensitivity to caramiphen edisylate or phenylpropanolamine hydrochloride |
|
| Drug Interactions |
|
MAO inhibitors, TCAs, NSAIDs |
|
| Usual Dosage |
|
Oral: 2-6 years: 1/2 teaspoonful every 4 hours 6-12 years: 1 teaspoonful every 4 hours Children >12 years and Adults: 1 capsule every 12 hours or 2 teaspoonfuls every 4 hours |
|
| Mental Health: Effects on Mental Status |
|
May cause restlessness or insomnia |
|
| Mental Health: Effects on Psychiatric Treatment |
|
Contraindicated with concurrent MAOI therapy |
|
| Dental Health: Local Anesthetic/Vasoconstrictor Precautions |
|
Use with caution since phenylpropanolamine is a sympathomimetic amine which could interact with epinephrine to cause a pressor response |
|
| Dental Health: Effects on Dental Treatment |
|
Up to 10% of patients could experience tachycardia, palpitations, and dry mouth; use vasoconstrictor with caution |
|
| Patient Information |
|
See individual agents. Pregnancy/breast-feeding precautions: Inform prescriber if you are or intend to be pregnant. Consult prescriber if breast-feeding. |
|
| Dosage Forms |
|
Capsule, timed release: Caramiphen edisylate 40 mg and phenylpropanolamine hydrochloride 75 mg Liquid: Caramiphen edisylate 6.7 mg and phenylpropanolamine hydrochloride 12.5 mg per 5 mL |
|
|
|
Copyright © 1978-2000 Lexi-Comp Inc. All Rights Reserved
